KRAS and pancreatic adenocarcinoma: Considering the association of alterations in KRAS and TP53 with worse outcomes of resected PAAD patients like previously described4,20, reduced DFS of the individuals carrying HLA-A02+B62+B44− could be partly attributed to their augmented KRAS G12D and TP53 mutations.